5-Year Survival in Gastric Adenocarcinoma with Epithelial and Stromal Versican Expression

Background & objective: gastric cancer is the second most frequent cause of cancer death worldwide, despite differences in incidence around the world. the majority of gastric cancer cases concern gastric adenocarcinoma, which has a fairly high 5-year survival rate when coupled with early-stage diagnosis. versican, a member of the aggregating chondroitin sulfate proteoglycans family, is accumulated predominantly in the tumor stroma. the aim of our study was to investigate versican expression in gastric adenocarcinoma. methods: in this study we investigated 80 patients with gastric adenocarcinoma who underwent gastrectomy. each sample was obtained from paraffin-embedded resected specimens of the stomach after histopathological diagnosis. patient follow-up was performed every 3 months after the beginning of data collection. survival analysis was calculated using the kaplan-meier method for univariate analysis. results: out of 80 patients with gastric adenocarcinoma, 76 cases (76.3%males and 23.7% females) completed the follow-up period. positive versican expression in tumor epithelial and stromal cells was found in 39.5% and 22.4% of tumors, respectively. shorter survival was observed among patients whose gastric adenocarcinoma expressed epithelial or stromal versican. conclusion: in summary, the present study suggests that versican is likely a prognostic biomarker that predicts a poor outcome in patients with gastric adenocarcinoma. comprehensive studies with larger sample sizes are needed.